JP Morgan Chase
ARLZ

JP Morgan Chase’s Aralez Pharmaceuticals Inc. ARLZ Stock Holding History

JP Morgan Chase’s Portfolio ARLZ Stock Details ARLZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-408
Closed – – 6015
2018
Q2 		$0 Hold
408
– – ﹤0.01% 5890
2018
Q1 		$1K Sell
408
-8,945
-96% -$15.6K ﹤0.01% 5346
2017
Q4 		$14K Sell
9,353
-1,234
-12% -$2.02K ﹤0.01% 5225
2017
Q3 		$23K Buy
10,587
+10,179
+2,495% +$13.6K ﹤0.01% 4620
2017
Q2 		$1K Hold
408
– – ﹤0.01% 4919
2017
Q1 		$1K Sell
408
-1,052
-72% -$3.95K ﹤0.01% 5015
2016
Q4 		$6K Buy
+1,460
New +$6.93K ﹤0.01% 4860
2016
Q3 		– Sell
-27,352
Closed -$90K – 5129
2016
Q2 		$90K Buy
+27,352
New +$103K ﹤0.01% 3896

Other funds holding ARLZ

GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

JP Morgan Chase's ARLZ Position: Q3 2018 in Review

JP Morgan Chase sold out of Aralez Pharmaceuticals Inc. (ARLZ) in Q3 2018, closing a stake of 408 shares.

JP Morgan Chase first reported a position in ARLZ in Q2 2016 and held it in 8 quarters. The position peaked at $90K in Q2 2016. 4 funds tracked by Wall St. Rank hold ARLZ as of Q3 2018.

  • JP Morgan Chase reported no remaining Aralez Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
  • JP Morgan Chase sold 408 Aralez Pharmaceuticals Inc. shares in Q3 2018.
  • JP Morgan Chase first reported a position in Aralez Pharmaceuticals Inc. in Q2 2016 and held it in 8 quarters.
  • JP Morgan Chase's Aralez Pharmaceuticals Inc. position peaked at $90K in Q2 2016.
  • 4 funds tracked by Wall St. Rank held Aralez Pharmaceuticals Inc. as of Q3 2018.

Based on JP Morgan Chase's 13F filing for Q3 2018, filed 7 Nov 2018.